Literature DB >> 21562100

Method for phenotypic detection of extended-spectrum beta-lactamases in enterobacter species in the routine clinical setting.

James Cohen Stuart1, Bram Diederen, Nashwan Al Naiemi, Ad Fluit, Niek Arents, Steven Thijsen, Bart Vlaminckx, Johan W Mouton, Maurine Leverstein-van Hall.   

Abstract

In 271 Enterobacter blood culture isolates from 12 hospitals, extended-spectrum beta-lactamase (ESBL) prevalence varied between 0% and 30% per hospital. High prevalence was associated with dissemination, indicating the potential relevance of infection control measures. Screening with cefepime or Vitek 2, followed by a cefepime/cefepime-clavulanate Etest, was an accurate strategy for ESBL detection in Enterobacter isolates (positive predictive value, 100%; negative predictive value, 99%).

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21562100      PMCID： PMC3147888          DOI： 10.1128/JCM.00864-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Extended-spectrum beta-lactamases in Enterobacter cloacae: underestimated but clinically significant!

Authors:  B Crowley; G Ratcliffe
Journal:  J Antimicrob Chemother       Date:  2003-03-28       Impact factor: 5.790

2.  Nosocomial spread of ESBL-positive Enterobacter cloacae co-expressing plasmid-mediated quinolone resistance Qnr determinants in one hospital in France.

Authors:  Anaïs Potron; Laurent Poirel; Sandrine Bernabeu; Xavier Monnet; Christian Richard; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2009-06-23       Impact factor: 5.790

3.  SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae.

Authors:  Dóra Szabó; Robert A Bonomo; Fernanda Silveira; A William Pasculle; Carla Baxter; Peter K Linden; Andrea M Hujer; Kristine M Hujer; Kathleen Deeley; David L Paterson
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Rapid emergence of resistance to cefepime during treatment.

Authors:  A P Limaye; R K Gautom; D Black; T R Fritsche
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

5.  Relapsing infection due to Enterobacter species: lessons of heterogeneity.

Authors:  A A Medeiros
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

6.  Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest.

Authors:  Asma Lat; Sarah A Clock; Fann Wu; Susan Whittier; Phyllis Della-Latta; Kathy Fauntleroy; Stephen G Jenkins; Lisa Saiman; Christine J Kubin
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

7.  Detection of SHV-type extended-spectrum beta-lactamase in Enterobacter isolates.

Authors:  Trent G Towne; James S Lewis; Monica Herrera; Brian Wickes; James H Jorgensen
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

8.  Molecular typing and characterization of extended-spectrum TEM, SHV and CTX-M beta-lactamases in clinical isolates of Enterobacter cloacae.

Authors:  Maurice Biendo; Claudia Manoliu; Geneviève Laurans; Sandrine Castelain; Brigitte Canarelli; Danièle Thomas; Farida Hamdad; Florence Rousseau; François Eb
Journal:  Res Microbiol       Date:  2008-09-19       Impact factor: 3.992

9.  Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection.

Authors:  Enno Stürenburg; Ingo Sobottka; Djahesh Noor; Rainer Laufs; Dietrich Mack
Journal:  J Antimicrob Chemother       Date:  2004-05-18       Impact factor: 5.790

10.  Enterobacter cloacae outbreak and emergence of quinolone resistance gene in Dutch hospital.

Authors:  Armand Paauw; Ad C Fluit; Jan Verhoef; Maurine A Leverstein-van Hall
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883
View more
  5 in total

1.  Modified CLSI extended-spectrum β-lactamase (ESBL) confirmatory test for phenotypic detection of ESBLs among Enterobacteriaceae producing various β-lactamases.

Authors:  Aggeliki Poulou; Evgenia Grivakou; Georgia Vrioni; Vassiliki Koumaki; Theodoros Pittaras; Spyros Pournaras; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2014-02-26       Impact factor: 5.948

2.  Evaluation of the Oxoid Brilliance™ CRE Agar for the detection of carbapenemase-producing Enterobacteriaceae.

Authors:  J Cohen Stuart; G Voets; W Rottier; S Voskuil; J Scharringa; K Van Dijk; A C Fluit; M Leverstein-Van Hall
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-02       Impact factor: 3.267

3.  Comparison of different phenotypic assays for the detection of extended-spectrum β-lactamase production by inducible AmpC-producing Gram-negative bacilli.

Authors:  E Willems; R Cartuyvels; K Magerman; M Raymaekers; J Verhaegen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-08       Impact factor: 3.267

4.  Extended-spectrum β-lactamase-producing E. coli septicemia among rectal carriers in the ICU.

Authors:  Minxue Liu; Mengjiao Li; Lijuan Wu; Qifei Song; Dan Zhao; Zhixing Chen; Mei Kang; Yi Xie
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

5.  Prevalence and impact of extended-spectrum β-lactamase production on clinical outcomes in cancer patients with Enterobacter species bacteremia.

Authors:  Sun Jong Kim; Ki-Ho Park; Jin-Won Chung; Heungsup Sung; Seong-Ho Choi; Sang-Ho Choi
Journal:  Korean J Intern Med       Date:  2014-08-28       Impact factor: 2.884
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.